Ricevi le ultime notizie sulle azioni Fulcrum Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di FULC

Ultime notizie per

Fulcrum Therapeutics

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics Inc

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aurora Cannabis

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Alumis

Alto Neuroscience

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Canopy Growth Corporation - Common Shares

Canopy Growth

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Cybin

Journey Medical Corporation - Common Stock

Journey Medical

Evolus

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

High Tide

LB Pharmaceuticals

LENZ Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

MediWound

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Omeros

SIGA Technologies

SNDL

Ventyx Biosciences

Zevra Therapeutics

Fulcrum Therapeutics (FULC) Previsione

Notizie

Utili

Quote.Nav.option-chain

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Comments

Fulcrum Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO